Researchers: More evidence needed for TAVR in young patients
“There is a high chance of reoperation in 10 to 15 years, which not only increases the cost substantially, but also leads to a higher-risk second procedure or surgery, as the patient will have aged and become more vulnerable to complications,”
https://www.cardiovascularbusiness....ease/more-evidence-needed-tavr-young-patients
If only there was a product that would last a lifetime.
Researchers: More evidence needed for TAVR in young patients...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.51 |
Change
-0.490(3.50%) |
Mkt cap ! $285.5M | |||
| Open | High | Low | Value | Volume |
| $14.05 | $14.05 | $13.40 | $234.3K | 17.15K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $13.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.70 | 614 | 1 |
View Market Depth
| Last trade - 15.59pm 08/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |